NeuExcell Therapeutics Secures Tens of Millions in Pre-A Financing to Advance In Situ Neural Regeneration Gene Therapy Platform

On August 30, NeuExcell Therapeutics, a company focused on gene therapy for neurodegenerative diseases and brain injuries, announced the completion of its Pre-A financing round, raising over ten million US dollars. The round was led by CoWin Ventures, with participation from YuanBio Venture Capital, Oriza Holdings, QY Capital, and Innocore Angel Fund.

Peter Tombros, Chairman of the Board of Directors, NeuExcell Therapeuticsstated, “It is a great honor to receive recognition from distinguished investors. Their support will drive the company to apply its proprietary neuroregenerative gene therapy platform to the treatment of various neurodegenerative diseases. The enthusiastic response to this financing round reflects investors’ endorsement of the company’s strategy and the advanced nature of its technology.”

CompanyProfessor Gong Chen, Co-Founder and Chief Scientific AdvisorHe stated, “We are thrilled to have the opportunity to accelerate the clinical translation of our in situ neuroregeneration technology, bringing effective treatments to tens of millions of patients worldwide. The world is in urgent need of breakthrough technologies like ours.”

Dr. Huang Xin, Managing Partner of CoWin Venturesstated, “We are delighted to have the opportunity to collaborate with NeuExcell’s experienced management team. NeuExcell’s proprietary technology has the potential to serve as a platform for treating multiple neurodegenerative diseases, offering breakthrough new therapies and renewed hope to patients who currently lack adequate treatment options.”

Dr. Huang Xin and Jonathan Sun will become new members of the NeuExcell Board of Directors.

NeuExcell is an early-stage gene therapy company with headquarters in Pennsylvania, USA, and Shanghai, China. NeuExcell is dedicated to treating neurological injuries and neurodegenerative diseases, with a mission to save patients’ lives. The company’s core technology is based on the scientific achievements of Professor Gong Chen, utilizing AAV gene therapy vectors to express neural transcription factors that convert astrocytes in situ into long-term functional neurons, thereby achieving neural repair. NeuExcell’s product pipeline covers major neurological injuries and neurodegenerative diseases, including stroke, Huntington’s disease, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, Parkinson’s disease, traumatic brain injury, spinal cord injury, and brain tumors.

CoWin Ventures is a dual-currency (USD and RMB) venture capital firm specializing in early-stage technology investments, championing a team culture of equality, transparency, sharing, and innovation. Founded in 2009, the firm focuses on healthcare and IT hard-tech sectors, with cumulative assets under management exceeding RMB 5 billion. It has provided funding and resource support to over one hundred outstanding teams and projects. CoWin Ventures has facilitated the successful public listings of more than ten high-tech enterprises, including Cytek (NASDAQ: CTKB), Conatus Pharmaceuticals* (NASDAQ: CNTB), Thrive* (NASDAQ: EXAS), InnoLight Technology (300308), Memblaze* (688286), Huaxing Zhiyuan* (000008), and Aolian Electronics (300585). Additionally, it has empowered numerous companies such as Taimei Medical Technology, Geneseeq Technology, HuaKe Precision, and Maxphotonics to emerge as leaders in their respective niche markets.*\*Note: The ticker symbols provided in the source text for CNTB and EXAS correspond to different entities than the Chinese names listed (Conatus/Cantabio and Exact Sciences/Thrive respectively). The translation preserves the original pairing as presented in the source text for fidelity, though CNTB is currently Cantabio Pharmaceuticals and EXAS is Exact Sciences.*